NCT03347994View on ClinicalTrials.gov

Minnelide in Adult Patients With Relapsed or Refractory Acute Myeloid Leukemia

PHASE1WithdrawnINTERVENTIONAL

Timeline

Start Date

April 30, 2018

Primary Completion Date

April 30, 2021

Study Completion Date

April 30, 2022

Conditions

Acute Myeloid Leukemia

Interventions

DRUG

Minnelide

Minnelide therapy may be administered for up to 12 cycles of 28 days are planned. If patients are receiving clinical benefit, treatment can continue beyond 12 cycles.